The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | CAMMA-1 : fixed-duration cevostamab shows durable responses in R/R multiple myeloma
Ravi Vij, MD, MBA, Washington University School of Medicine, St. Louis, MO, discusses results from Arm A of the CAMMA-1 trial (NCT04910568) evaluating fixed-duration cevostamab, an FcRH5-targeted bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma. He highlights an overall response rate of approximately 70%, deep responses including MRD negativity, and durable responses after treatment completion, with a manageable safety profile and infections remaining an important consideration. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
